新辅助化疗后行根治性切除术治疗局部转移性膀胱癌患者的临床研究  

Clinical study of radical resection for locally metastatic bladder cancer after neoadjuvant chemotherapy

作　　者：林建群[1] 章锐鸿 陈锡彬[1] 吴佩玲[1] 王乐浩 许哲[1] 

机构地区：[1]汕头市第二人民医院泌尿外科,广东汕头515000

出　　处：《国际泌尿系统杂志》2016年第4期488-490,共3页International Journal of Urology and Nephrology

基　　金：汕头市科技计划项目（20150406）

摘　　要：目的考察新辅助化疗后行根治性切除术治疗局部转移性膀胱癌患者的临床疗效。方法回顾性分析局部转移性膀胱癌患者临床资料37例，依据是否接受新辅助化疗分为观察组（20例）和对照组（17例）。观察组患者使用顺铂、吉西他滨新辅助化疗后行根治性切除术治疗。对照组患者接受根治性切除术治疗。随访记录患者化疗效果、前后肿瘤大小、不良反应和生存期。结果化疗后患者治疗有效率75．0％（15／20），肿瘤直径显著降低（P〈0．01）。不良反应总体发生率为70．0％（14／20），且主要为Ⅰ～Ⅱ级。观察组患者中位生存期41个月显著高于对照组的26个月（P〈0．05）。结论新辅助化疗可以获得较高应答率，显著缩小肿瘤，结合手术治疗可延长患者生存期。Objectives To investigate the clinical effect of radical resection for locally metastat- ic bladder cancer after neoadjuvant chemotherapy. Methods A retrospective analysis of 37 patients with local metastasis of bladder cancer who were divided into observation group （20 cases） and control group （17 cases） according to their therapy. Patients in observation group were treated by cisplatin and gemcitabine neoadjuvant chemotherapy followed by radical resection surgery and patients in control group were treated by radical resection surgery only. The effect of chemotherapy, tumor size before and after, adverse reactions and survival rate were recorded and observed. Results The effective rate of chemotherapy was 75.0% （15/20） , and the diameter of tumor was significantly decreased after treatment（ P 〈 0.01 ）. The overall incidence of adverse reactions was 70.0% （ 14/20）, and most of them were Ⅰ or Ⅱ grade. The median survival time of the observation group was 41 months which significantly higher than 26 months in control group （ P 〈 0.05）. Conclusions Neoadjuvant chemotherapy can achieve a high response rate, significantly reduce the tumor, prolong the survival time of patients com- bined with surgical operation .

关 键 词：膀胱肿瘤 膀胱切除术 肿瘤转移 化学疗法 辅助 

分 类 号：R737.14[医药卫生—肿瘤]